Financial Data and Key Metrics Changes - The company reported adjusted EPS of $2.14, reflecting an 8.6% growth compared to the first quarter of 2022 [3][10] - Organic sales growth was 13.6% in the quarter, with US organic sales growth at 12.6% and international organic sales growth at 16.6% [10][100] - Adjusted gross margin was 63.2%, approximately 90 basis points unfavorable from the first quarter of 2022, primarily due to increased manufacturing and supply chain costs [13] - Adjusted operating margin was 21.1% of sales, approximately 70 basis points unfavorable to the first quarter of 2022 [14] Business Line Data and Key Metrics Changes - Endoscopy had US organic sales growth of 16.2%, driven by strong growth across major businesses [11] - Medical had US organic sales growth of 13.2%, benefiting from improved product supply [11] - Orthopedics and Spine had constant currency sales growth of 15.1%, with US organic growth of 13.3% and international growth of 20.3% [12] - Instruments had US organic sales growth of 8.9%, led by double-digit growth in the Surgical Technology business [107] Market Data and Key Metrics Changes - The international business continued to be a growth engine, with strong results in Europe, Australia, Canada, and Japan, while China experienced negative growth due to COVID and volume-based procurement [100][108] - The US Other Orthopedics segment declined organically by 14.8%, primarily due to a shift towards more rentals related to Mako installations [109] Company Strategy and Development Direction - The company is focused on maintaining a strong order book for capital equipment and is optimistic about the ongoing product super cycle [104][138] - Management emphasized the importance of innovation and product launches, including the Neptune S waste management system and the Mako 2.0 software [7][130] - The company plans to continue pursuing acquisitions as a key part of its growth strategy, with a focus on smaller tuck-in deals for the current year [45][161] Management's Comments on Operating Environment and Future Outlook - Management noted a gradual improvement in component availability and lessened supply chain constraints [3] - The company expects full-year organic sales growth to be in the range of 8% to 9%, with adjusted EPS guidance raised to $10.05 to $10.25 [101][112] - Management remains cautious about inflationary pressures and the potential impact of foreign exchange rates on sales and EPS [138] Other Important Information - The company ended the first quarter with $1.8 billion in cash and marketable securities and total debt of $13.1 billion [111] - Adjusted R&D spending was 6.5% of sales, a decrease from the previous year, while adjusted SG&A was 35.6% of sales, reflecting normalization of sales force expansion [110] Q&A Session Summary Question: What are the growth rates in Q1 for Ortho and MedSurge? - Management indicated that the procedures are ramping nicely and capital demand remains strong, contributing to optimism for the full year [113] Question: Can you provide insights on the performance of the knee and hip business? - The knee business continues to show strong performance, driven by Mako growth and cementless growth, while the hip business is expected to grow above market due to the Insignia Stem launch [116][178] Question: What is the outlook for the ASC market? - Management noted steady progression in both hips and knees, with double-digit penetration expected to continue as more procedures move to ASCs [25] Question: How is the company addressing competitive pressures in the Mako business? - Management acknowledged competitive pressures have shifted customer behavior but emphasized that they are winning at a high rate and installations are being utilized effectively [186] Question: What is the company's approach to acquisitions? - The company is focusing on smaller tuck-in acquisitions for the current year, with plans to pursue larger deals in the future if cash flow remains strong [161]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION (Exact name of registrant as specified in its charter) | Michigan | | | 38-1239739 | | --- | --- | --- | --- | | (State of incorporation) | | | (I.R.S. ...

Stryker Corporation (NYSE:SYK) Q4 2022 Earnings Conference Call January 31, 2023 4:30 PM ET Company Participants Kevin Lobo - Chair and CEO Glenn Boehnlein - Chief Financial Officer Jason Beach - Vice President, Investor Relations Conference Call Participants Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Vijay Kumar - Evercore Shagun Singh - RBC Ryan Zimmerman - BTIG Vik Chopra - Wells Fargo Matt Miksic - Barclays Pito Chickering - Deutsche Bank Steven Lichtman - Oppenheimer Drew Ranieri - Morgan ...

Stryker Corporation. (NYSE:SYK) 5th Annual Evercore ISI HealthCONx Conference 2022 December 1, 2022 8:50 AM ET Company Participants Kevin Lobo - Chief Executive Officer Jason Beach - Vice President, Investor Relations Lara Mordoh - Senior Director, Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks everyone for joining us this morning. A pleasure to have with us the team from Stryker. We have CEO Kevin Lobo with us this morning. And from investor relations, ...

Stryker Corporation (NYSE:SYK) Q3 2022 Earnings Conference Call October 31, 2022 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Glenn Boehnlein - Chief Financial Officer Jason Beach - Vice President, Investor Relations Conference Call Participants Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Matthew O'Brien - Piper Sandler Joshua Jennings - Cowen & Co. Matthew Miksic - Barclays Rick Wise - Stifel Drew Ranier ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION (Exact name of registrant as specified in its charter) | Michigan | | 38-1239739 | | --- | --- | --- | | (State of incorporation) | | (I.R.S. ...

Stryker Corporation (NYSE:SYK) Q2 2022 Earnings Conference Call July 26, 2022 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Glenn Boehnlein - Chief Financial Officer Jason Beach - Vice President, Investor Relations Conference Call Participants Robbie Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore Pito Chickering - Deutsche Bank Matthew O’Brien - Piper Sandler Joanne Wuensch - Citi Joshua Jennings - Cowen Kyle Rose - Canaccord Chris Pasquale - Nephr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ...

Stryker Corp (NYSE:SYK) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Preston Wells - VP, IR Glenn Boehnlein - VP & CFO Conference Call Participants Vijay Kumar - Evercore ISI Matthew Miksic - Crédit Suisse Robert Marcus - JPMorgan Chase & Co. Jason Wittes - Loop Capital Markets Danielle Antalffy - SVB Leerink Andrew Stafford - Piper Sandler & Co. David Saxon - Needham & Company Ryan Zimmerman - BTIG Andrew Ranieri - Morgan Stanley Ric ...